In a preclinical model, a TGF-β inhibitor, SRI31277, was administered to mice with multiple osteolytic lesions and was shown to decrease the tumor burden and decrease phosphorylated SMAD2, which was associated with decrease in osteoclasts and increase in osteoblasts [193]. This evidence concerns the gene SMAD2 and neoplasm.